The White House has issued an executive order aimed at accelerating research and clinical trials for psychedelic drugs, including psilocybin, MDMA, and ibogaine. While this move does not change the legal status of these substances, it marks a significant step towards establishing a medical, evidence-based framework for alternative medicines, similar to the approach taken with cannabis.
Psychedelics have been hindered by limited safety and clinical data, whereas cannabis has had a head start in terms of commercial development. The executive order aims to address this disparity by promoting research and clinical trials for psychedelic drugs, thereby legitimizing an industry that has long operated in the shadows.
The move is seen as a positive step forward by advocates, who are hopeful that it will lead to greater access to these substances for therapeutic purposes. However, some experts are cautious, noting that the federal process can be slow-moving and prone to delays.
This concern is echoed by the experience with cannabis, which has been the subject of a federal review process for several months. Despite an initial directive from President Trump to reschedule cannabis, progress has stalled, with the Drug Enforcement Administration’s review still ongoing.
The slow pace of the federal process is attributed to the complex interplay between scientific evaluation, legal standards, and politics. According to Shawn Hauser, a partner at cannabis law firm Vicente LLP, the process has been “slow and frustrating” for stakeholders, who have been fighting for decades to reclassify marijuana.
The White House’s executive order on psychedelics has sparked hope that the industry will finally receive the recognition and support it deserves. However, only time will tell if this move will lead to meaningful change or if it will fall victim to the same slow-moving federal process that has plagued cannabis.
